AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25311593
Drug: Daclatasvir 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 12 weeks (60 mg once daily) + peginterferon alfa-2a + ribavirin
Trial: 25311593
Drug: Daclatasvir 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir 16 weeks (60 mg once daily) + peginterferon alfa-2a + ribavirin
Trial: 21632064
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's Wort (810 mg/day)
Trial: 16876451
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice and 0.5 g MCT per kg lean body mass
Trial: 15702625
Drug: ACE inhibitors,
RxNorm normalized name: ACE INHIBITORS, PLAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors, CCBs, and conventional treatment (diuretics/beta-blockers)
Trial: 10423078
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure lowering treatments
Trial: 15702625
Drug: Regimens based
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimens based on different drug classes
Trial: 25889313
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide (OCT) 0.3 mg/day for 3 days
Trial: 25889313
Drug: Scopolamine butylbromide
RxNorm normalized name: Scopolamine butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine butylbromide (SB) 60 mg/day for 3 days
Trial: 10687323
Drug: Less parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less parenteral hydration
Trial: 10687323
Drug: Pain relief
RxNorm normalized name: Pain Relief
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain relief treatment
Trial: 1363053
Drug: Bupivacaine (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (high concentration, 5 mg/ml; low concentration, 2.5 mg/ml) with volumes of 15-20 ml (high) or 5-10 ml (low) injected at C6 or C7
Trial: 1363053
Drug: Injection toward
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection toward C7 instead of C6
Trial: 3887553
Drug: Pirenzepine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (50 mg twice daily)
Trial: 30878612
Drug: Cupping treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cupping treatment
Trial: 21559322
Drug: Benzodiazepine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine treatment
Trial: 26637993
Drug: Cardiovascular seven‐faceted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiovascular seven‐faceted screening examinations including low‐dose non‐contrast CT scan, brachial and ankle blood pressure index, telemetric assessment of heart rhythm, cholesterol and plasma glucose measurement.
Trial: 20878375
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block (SCPB) with 20 mL of a 1:1 mixture of 0.5% bupivacaine and 2% lidocaine
Trial: 20878375
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg·kg⁻¹ iv after dural closure
Trial: 16647354
Drug: Standard drain
RxNorm normalized name: Standard Drainable Pouch One Piece
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drain removal (< 30 mL drainage in 24 hours or postoperative day 14)
Trial: 10372699
Drug: GnRHa treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa treatment only (Group A)
Trial: 1679252
Drug: Alternative somatic
RxNorm normalized name: Bos taurus somatic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative somatic treatments for schizophrenia
Trial: 7237025
Drug: DDAVP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (1 deamino‐8‐D‐arginine vasopressin) at a dose of 1 microgram
Trial: 7237025
Drug: DDAVP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (1 deamino‐8‐D‐arginine vasopressin) at a minimum effective dose of 2 ng/kg
Trial: 30784208
Drug: PF‐04895162 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04895162 (300 mg twice daily for 2 weeks)
Trial: 28106903
Drug: Rd continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rd continuous (lenalidomide plus low-dose dexamethasone)
Trial: 28106903
Drug: Rd18 (lenalidomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rd18 (lenalidomide plus low-dose dexamethasone for 18 cycles)
Trial: 24297841
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg racemic ketamine (Keta‐Race)
Trial: 24297841
Drug: 9 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg/kg S‐ketamine (S‐Keta)
Trial: 12607287
Drug: Fluvoxamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine treatment for 12 weeks
Trial: 12607287
Drug: Fluvoxamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine treatment for 6 weeks
Trial: 10691121
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (dosage adjusted on clinical grounds)
Trial: 22378321
Drug: Intraoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous and postoperative oral clindamycin for 7 days
Trial: 10598660
Drug: CI-980 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-980 at 3.5 mg/m2/day for 3 days (continuous intravenous infusion)
Trial: 10598660
Drug: CI-980 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-980 at 4.2 mg/m2/day with G-CSF (for brain tumor patients)
Trial: 10598660
Drug: CI-980 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-980 at 5 mg/m2/day with G-CSF (for solid tumor patients)
Trial: 10598660
Drug: CI-980 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-980 at 5 mg/m2/day regimen
Trial: 1425821
Drug: Bromocriptine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine monotherapy (Group 1)
Trial: 1425821
Drug: Early combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combination of bromocriptine and levodopa (Group 2A)
Trial: 30021625
Drug: Remifentanil 2
RxNorm normalized name: remifentanil 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 2 ng/mL (group R2)
Trial: 30021625
Drug: Remifentanil 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 4 ng/mL (group R4)
Trial: 30021625
Drug: Remifentanil 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 6 ng/mL (group R6)
Trial: 18586813
Drug: Interdisciplinary programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary programme (physiotherapy, occupational therapy, physical education)
Trial: 11805349
Drug: L‐adrenaline (0.1ml/kg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐adrenaline (0.1ml/kg/dose in 1 in 10,000 solution)
Trial: 11805349
Drug: Salbutamol (0.1mg/kg/dose)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.1mg/kg/dose)
Trial: 8749227
Drug: Methylcobalamin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcobalamin + Steroid
Trial: 19942723
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid
Trial: 1386825
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil containing eicosapentaenoic acid (4.1 g/day) and docosahexaenoic acid (3.6 g/day)
Trial: 6837242
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution and glucose
Trial: 30644740
Drug: Citrus sinensis
RxNorm normalized name: CITRUS SINENSIS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus sinensis cv. 'Cara Cara' orange juice (500 mL daily)
Trial: 30644740
Drug: Citrus sinensis
RxNorm normalized name: CITRUS SINENSIS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus sinensis cv. 'Bahia' orange juice (500 mL daily)
Trial: 29336387
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 mcg/kg loading dose over 15 minutes, followed by 0.5 mcg/kg/h maintenance infusion for 2 hours)
Trial: 22344576
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg every 4 weeks plus MTX
Trial: 17957910
Drug: Pueraria mirifica
RxNorm normalized name: PUERARIA MIRIFICA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pueraria mirifica (PM) 50 mg daily, Group A
Trial: 17957910
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE) 0.625 mg daily with/without medroxyprogesterone acetate (MPA) 2.5 mg, Group B
Trial: 16360062
Drug: Sequential cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential cardiac resynchronization therapy (CRT) for six months
Trial: 16360062
Drug: Sequential cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential cardiac resynchronization therapy (CRT)
Trial: 16360062
Drug: Simultaneous cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous cardiac resynchronization therapy (CRT)
Trial: 12463580
Drug: Neuraxial anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuraxial anesthesia with selective factor Xa inhibitor fondaparinux
Trial: 2338698
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg per day (n = 17)
Trial: 2338698
Drug: Nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 20 mg daily (n = 18)
Trial: 14658
Drug: Flunitrazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (1 mg and 2 mg)
Trial: 31136460
Drug: Strict posturing
RxNorm normalized name: Euphrasia stricta extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strict posturing and bilateral patching overnight (Treatment A)
Trial: 31136460
Drug: Posturing alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posturing alone (Treatment B)
Trial: 25019968
Drug: Endoscopic flushing
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic flushing with pronase (50 mL of water, pronase, sodium bicarbonate, and DMPS)
Trial: 17765048
Drug: Short-course antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course antibiotic regimens (7 days or less)
Trial: 17765048
Drug: Extended-course antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-course antibiotic regimens (>7 days)
Trial: 12351249
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at 0.83 micro g. kg(‐1). min(‐1) (Group R)
Trial: 12351249
Drug: Fentanyl bolus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl bolus, small dose, at 12 micro g/kg (Group FLD)
Trial: 12351249
Drug: Fentanyl bolus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl bolus, moderate dose, at 24 micro g/kg (Group FMD)
Trial: 9832574
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (40 parts per million)
Trial: 8137928
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g orally)
Trial: 2733576
Drug: 6% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% glucose solution
Trial: 2733576
Drug: 6% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% sucrose solution
Trial: 2733576
Drug: 6% fructose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% fructose solution
Trial: 786825
Drug: High-dose neurotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose neurotropic vitamins (Neurotrat forte)
Trial: 31733182
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg) plus aspirin (75 to 100 mg) once daily
Trial: 31733182
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg) plus aspirin (75 to 100 mg) once daily
Trial: 20329690
Drug: Levonorgestrel regimen
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel regimen (0.75 mg taken twice in 12-hour intervals within 72 hours after unprotected intercourse)
Trial: 20329690
Drug: Yuzpe method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yuzpe method (two HD contraceptive pills)
Trial: 15047681
Drug: Tomato puree
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato puree supplementation (96 g/day for three weeks)
Trial: 8392150
Drug: Sumatriptan (SC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (SC, 6 mg; three attacks)
Trial: 12975409
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker
Trial: 30384381
Drug: Genotype-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided treatment allocation (G‐allele carriers receiving naltrexone)
Trial: 30384381
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (random treatment allocation to acamprosate or naltrexone)
Trial: 27743738
Drug: Clear Cell
RxNorm normalized name: Umbilical Cord Blood Mononuclear Cells Conditioned Medium
DrugBank: Human umbilical cord blood mononuclear cell-conditioned medium (DB15724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear Cell Carcinoma (CC)
Trial: 24614165
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who experienced severe adverse drug reactions
Trial: 22471125
Drug: Acupuncture-medication group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture-medication group (Baihui (GV 20) and Fengchi (GB 20) acupoints)
Trial: 22471125
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group (Nimodipine)
Trial: 22471125
Drug: Acupuncture-medication group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture-medication group
Trial: 19167590
Drug: Short-term danazol
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term danazol treatment (200 mg/d for 4 weeks)
Trial: 19167590
Drug: Long-term danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term danazol treatment (mean dose of 170 mg/d for >2 years)
Trial: 15500196
Drug: benidipine hydrochloride
RxNorm normalized name: Benidipine hydrochloride
DrugBank: Benidipine (DB09231)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benidipine hydrochloride (4 mg/day)
Trial: 15500196
Drug: amlodipine (5-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine (5-7.5 mg/day)
Trial: 15500196
Drug: benidipine hydrochloride
RxNorm normalized name: Benidipine hydrochloride
DrugBank: Benidipine (DB09231)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benidipine hydrochloride (4-8 mg/day)
Trial: 9056051
Drug: Lazabemide 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazabemide 100 mg twice daily
Trial: 9056051
Drug: Lazabemide 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazabemide 350 mg twice daily
Trial: 9056051
Drug: Lazabemide (100-350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazabemide (100-350 mg)
Trial: 9056051
Drug: Lazabemide (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazabemide (single and multiple doses)
Trial: 9056051
Drug: Lazabemide (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazabemide (multiple dosing)
Trial: 3021189
Drug: Aspirin 10
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 10 mg
Trial: 3021189
Drug: Aspirin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (in vivo)
Trial: 22092512
Drug: Mandibular two-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular two-implant overdentures (IODs)
Trial: 20528908
Drug: Bortezomib treatment
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib treatment (four cycles, initially as monotherapy, then combined with glucocorticoid from cycle two to four)
Trial: 20528908
Drug: Bortezomib treatment
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib treatment with glucocorticoid
Trial: 20528908
Drug: Glucocorticoid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid treatment in vitro
Trial: 15101020
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.5-3.0)
Trial: 27281490
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg for 14 days
Trial: 2510530
Drug: Cefotaxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (1 g single preoperative dose)
Trial: 2510530
Drug: Cefoxitin (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (four 2-g doses)
Trial: 27873516
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose EC‐MPS with low dose CsA
Trial: 27873516
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose CsA with low dose EC‐MPS
Trial: 25928131
Drug: Integrative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative treatment (IT)
Trial: 23867209
Drug: Synbiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic therapy (7 days preoperative and 10 days postoperative)
Trial: 20619394
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without synbiotic therapy
Trial: 22089773
Drug: L-Carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine supplementation (1 g/dose, intravenously three times a week after each HD session)
Trial: 22089773
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no L-Carnitine supplementation)
Trial: 19933081
Drug: Liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin 40 mg/m(2) intravenously every 28 days
Trial: 19933081
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel 36 mg/m(2) intravenously days 1, 8, and 15, repeated every 28 days
Trial: 9374563
Drug: Acetaminophen 12
RxNorm normalized name: acetaminophen 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 12 mg/kg
Trial: 7955970
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance during pregnancy (0.05 U kg-1 intravenously)
Trial: 7955970
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance after pregnancy (0.05 U kg-1 intravenously)
Trial: 3790639
Drug: Naltrexone, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone, 300 mg/day
Trial: 31206613
Drug: N-acetyl-cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-cysteine (NAC) 50 mg/kg IV plus 500 mg oral twice per day for 3 months
Trial: 28729158
Drug: Dolutegravir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir plus abacavir and lamivudine (single-tablet regimen)
Trial: 28729158
Drug: Ritonavir-boosted atazanavir
RxNorm normalized name: atazanavir and ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine (three-tablet combination)
Trial: 21823280
Drug: Acupoint catgut
RxNorm normalized name: CATGUT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint catgut embedding combined vessel pricking therapy (group A)
Trial: 21823280
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Sulfasalazine (SASP) (group B)
Trial: 16768632
Drug: Extended-release dexmethylphenidate
RxNorm normalized name: dexmethylphenidate Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release dexmethylphenidate (d-MPH-ER) 20 mg/day